The INT²GRATE Variant Portal is a comprehensive resource developed by the INT²GRATE Data Coordinating Center (DCC), the computational arm of the INT²GRATE Oncology Consortium. The INT²GRATE Variant Portal provides evidence-based insights for germline variants within cancer syndrome-specific contexts. Built on the INT²GRATE Evidence Framework (VEF), the Portal integrates four key sources of evidence. Germline Genetics Evidence includes assessment of zygosity and differential diagnoses relevant to cancer syndromes. Clinical Genetics Evidence incorporates syndrome-specific clinical history, personal, and family features. Somatic Genetics Evidence provides detailed information on the somatic allele locus and relevant somatic alterations for each cancer syndrome. Tumor-derived Evidence captures tumor pathology, tumor types, and defining features specific to each syndrome. The INT²GRATE Variant Portal is a freely available resource that provides comprehensive evidence for germline variants to users, including cancer geneticists, oncologists, researchers, and other healthcare professionals involved in cancer-related care and variant assessment.
Application of INT²GRATE Evidence Framework in Precision Oncology
This schematic illustrates how the INT²GRATE Evidence Framework is applied to assess the clinical relevance and actionability of an INT²GRATE Variant in relation to its associated cancer syndrome.
Comprehensive Evidence Gathering to Generate an INT²GRATE Variant
This schematic illustrates how an INT²GRATE Variant is generated through the integration of syndrome-specific germline, clinical, somatic, and tumor-derived evidence sources. The figure is adapted from Advancing the Landscape of Clinical Actionability in Von Hippel-Lindau Syndrome: An Evidence-based Framework from the INT²GRATE Oncology Consortium [Manuscript submitted for publication].
contact information
Contact us
For questions about the INT²GRATE | Variant Portal or interest in the INT²GRATE Consortium membership or collaboration, please contact us by visiting our contact page.
For information about the INT²GRATE Oncology Consortium, visit the consortium webpage.